Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Urinary Bladder Neoplasms 1Pancreatic carcinoma, familial 1Pancreatic Intraductal Neoplasms 1Cranial Nerve Diseases 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 51Magnetic Resonance Spectroscopy 34Temozolomide 28pembrolizumab 24Bevacizumab 24Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10Blood Specimen Collection 9trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5Lomustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Ferrosoferric Oxide × 1 year × Clear all
NCT03270059 2026-02-27

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

OHSU Knight Cancer Institute

Phase 2 Recruiting
150 enrolled
CNS

Brain Neoplasms, Cranial Nerve Diseases, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡